Vimarsana
Biggest News Aggregation in the World

Page 4 - Eceptor News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Eceptor. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Eceptor Today - Breaking & Trending Today

Study reveals unexpected vulnerability of lung immune cells to SARS-CoV-2 - Vimarsana News

Study reveals unexpected vulnerability of lung immune cells to SARS-CoV-2

The lung-cell type that's most susceptible to infection by SARS-CoV-2, the virus that causes COVID-19, is not the one previously assumed to be most vulnerable.

Popular diabetes drugs not linked to thyroid cancer risk, study finds - Vimarsana News

Popular diabetes drugs not linked to thyroid cancer risk, study finds

Drugs known as GLP-1 analogs have become increasingly popular to treat diabetes and obesity, but there have been concerns that they might increase the risk of thyroid cancer.

Tiam1 inhibition mitigates morphine tolerance and hyperalgesia in mouse model - Vimarsana News

Tiam1 inhibition mitigates morphine tolerance and hyperalgesia in mouse model

Morphine and other opioids are vital to treat severe and chronic pain. However, they have two problems -; prolonged use creates morphine tolerance, where ever-increasing doses are needed for the same pain relief, and paradoxically, prolonged use also can create an extreme sensitivity to pain, called hyperalgesia.

Research identifies how leukemia develops resistance to first line treatments - Vimarsana News

Research identifies how leukemia develops resistance to first line treatments

Relapses in a common form of leukemia may be preventable following new research which has identified how the cancer develops resistance to first line treatments.

Novel combination therapy shows promise in difficult-to-treat endometrial cancer, study finds - Vimarsana News

Novel combination therapy shows promise in difficult-to-treat endometrial cancer, study finds

In a small, investigator-initiated phase 2 study by Dana-Farber Cancer Institute investigators, a novel combination of an antibody-drug conjugate and an immune checkpoint inhibitor showed notable activity in pre-treated patients with a difficult-to-treat form of endometrial cancer.